Volume 12, Issue 3 pp. 158-164
REVIEW ARTICLE

Anti-GQ1b antibody: Recent topics

Ayumi Uchibori

Corresponding Author

Ayumi Uchibori

Department of Neurology, Faculty of Medicine, Kyorin University, Tokyo, Japan

Correspondence

Ayumi Uchibori, PhD, Department of Neurology, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan.

Email: [email protected]

Search for more papers by this author
First published: 23 July 2021
Citations: 1

Abstract

Studies on antibodies against glycolipids, mainly gangliosides, have advanced the understanding of the pathophysiology of Guillain–Barré syndrome. Glycolipid antibody research began with the study of isolated ganglioside antigens, and further expanded that area with the discovery of antibodies against complex antigens of two glycolipids. In Fisher syndrome-related disorders, immunoglobulin G (IgG) anti-GQ1b antibody is detected at a high rate, but 10–30% of the cases are antibody-negative. Recently, an antibody that requires Ca2+ to react with ganglioside GQ1b (Ca2+-dependent GQ1b antibody) was discovered in the antibody-negative cases. Ca2+ interacts with the disialosyl group (NeuAc[α2-8]NeuAc[α2-])of GQ1b, and the antibody is thought to recognize the structure to which Ca2+ is bound. Anti-GQ1b antibody is considered to be more involved in Fisher syndrome-related disorders than was previously shown.

CONFLICT OF INTEREST

The author declares no conflict of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.